Paul Boni brings more than three decades of capital-markets insight and operational finance leadership to OrphAI Therapeutics, where he serves as Chief Financial Officer. In this role he guides corporate finance strategy, fundraising, and long-range planning for the company’s clinical and pre-clinical rare-disease programs. He began his career as an equity analyst and portfolio manager covering biotechnology, where he developed a deep understanding of fundraising, capital markets, and the finance ecosystem that supports growing biotechnology companies. Mr. Boni previously oversaw investor development and strategy at ContraFect Corporation, a publicly traded company focused on anti-infective drug development, and led a global team of nearly 400 associates worldwide at Grail Research, a strategic research/consulting group, providing strategic market intelligence to life-science clients. As Chief Financial Officer of Manus Bio, a privately held synthetic biology company, he helped drive the transformational acquisition of NutraSweet, which added in-house manufacturing and commercial product sales to the company's existing research and development capabilities. With a unique blend of Wall Street acumen and hands-on operating experience—from discovery-stage startups to NASDAQ-listed companies—Paul Boni partners with scientific and clinical teams to secure the resources and strategic relationships needed to accelerate novel therapies to patients worldwide.
